Gloria Borra
Novara, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].
Journal: Cancer treatment and research communications
Published: August 25, 2026
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.
Journal: The oncologist
Published: September 19, 2025
Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.
Journal: JTO clinical and research reports
Published: June 03, 2025
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study.
Journal: Cancer treatment and research communications
Published: March 24, 2025
First report of Central-line-associated bloodstream infection (CLAB- SI) due to Enterococcus raffinosus (ER) in a cancer patient.
Journal: La Clinica terapeutica
Published: December 04, 2023
Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line.
Journal: Future oncology (London, England)
Published: March 22, 2023
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 28, 2022
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 14, 2021
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
Journal: Leukemia
Published: June 25, 2020
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 16, 2019
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: August 09, 2019
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 26, 2019
Last Updated: 09/26/2026